Journal
Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
Publication Date
1-1-2022
Volume
14
Issue
1
First Page
e12367
Document Type
Open Access Publication
DOI
10.1002/dad2.12367
Rights and Permissions
Wang, G, Li, Y, Xiong, C, et al. Evaluation of dose-dependent treatment effects after mid-trial dose escalation in biomarker, clinical, and cognitive outcomes for gantenerumab or solanezumab in dominantly inherited Alzheimer's disease. Alzheimer's Dement. 2022; 14:e12367. https://doi.org/10.1002/dad2.12367 © 2022 The Authors. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring published by Wiley Periodicals, LLC on behalf of Alzheimer's Association. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
Recommended Citation
Wang, Guoqiao; Li, Yan; Xiong, Chengjie; McDade, Eric; Clifford, David B; Mills, Susan L; Santacruz, Anna M; Aschenbrenner, Andrew J; Hassenstab, Jason; Benzinger, Tammie L S; Gordon, Brian A; Fagan, Anne M; Coalier, Kelley A; Libre-Guerra, Jorge J; McCullough, Austin; Joseph-Mathurin, Nelly; Chen, Charles D; Bateman, Randall J; and et al., "Evaluation of dose-dependent treatment effects after mid-trial dose escalation in biomarker, clinical, and cognitive outcomes for gantenerumab or solanezumab in dominantly inherited Alzheimer's disease." Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring. 14, 1. e12367 (2022).
https://digitalcommons.wustl.edu/oa_4/2528
Department
ICTS (Institute of Clinical and Translational Sciences)
Additional Links
Supplemental material is available for this article at publisher site.
